Strides Pharma sells its manufacturing site in Singapore for $15 million, according to ET HealthWorld


New Delhi: On Friday, Strides Pharma Science (Strides) announced that it has reached a binding agreement with Rxilient Biohub to sell its manufacturing facility in Singapore for $15 million.

The proceeds from the transaction will be used to reduce debt.

This sale will also enable Strides to cut annual costs by Rs 75 crore. This cost reduction will include a decrease of Rs 18 crore in operating expenses and Rs 57 crore in depreciation and operating lease expenses.

According to Strides, the transaction will lead to an increase in earnings per share (EPS) without affecting revenues.

Last year, the Singapore manufacturing site was closed down as part of the company’s manufacturing network optimization and cost reduction programs implemented in the FY23 reset strategy.

“This transaction represents the successful culmination of our efforts to optimize our manufacturing network and focus on driving profitability and operational efficiency,” the company stated in a press release.

The transaction is expected to close in Q3FY24 upon receiving the necessary approvals.

  • Published On Oct 28, 2023 at 06:41 AM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get the latest insights and analysis.

Download the ETHealthworld App

  • Get real-time updates
  • Save your favorite articles

Scan to download the App

Brought to you by News Live Updates


Please enter your comment!
Please enter your name here